Does Medicare Cover Wegovy for Heart Disease in 2026?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part D plans began covering Wegovy for cardiovascular risk reduction in March 2024 after FDA approval for heart disease prevention, but only for patients who meet specific BMI and cardiovascular criteria
• Typical Medicare Part D copays for Wegovy range from $350 to $650 per month on specialty tiers, with no manufacturer savings card allowed for Medicare beneficiaries
• Coverage requires documented cardiovascular disease plus BMI of 27 or higher, not weight loss alone, and most plans mandate prior authorization with strict clinical documentation
• Compounded semaglutide costs $179 to $279 monthly without insurance involvement, making it the primary alternative for Medicare patients facing unaffordable specialty copays

Direct answer (40-60 words)

Yes, Medicare Part D plans cover Wegovy for cardiovascular risk reduction as of 2024, but only for patients with established cardiovascular disease and BMI 27 or higher. Coverage excludes weight loss as a standalone indication. Typical copays are $350 to $650 monthly on specialty tiers. Prior authorization is required by 94% of Part D plans.

Table of contents

1. The 2024 FDA approval that changed Medicare coverage
2. Exactly who qualifies under Medicare's cardiovascular indication
3. What most articles get wrong about the coverage gap
4. Real Medicare Part D copay scenarios (5 plan examples)
5. The prior authorization requirements every plan uses
6. Why the Novo Nordisk savings card doesn't apply to Medicare
7. Medicare Advantage vs Original Medicare Part D coverage differences
8. The coverage gap (donut hole) impact on annual Wegovy costs
9. State Medicaid coverage for dual-eligible patients
10. The compounded semaglutide alternative for Medicare patients
11. How to verify your specific plan's coverage in 10 minutes
12. FAQ

The 2024 FDA approval that changed Medicare coverage

On March 8, 2024, the FDA approved Wegovy for a second indication: reducing risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight (Lincoff et al., New England Journal of Medicine 2023).

This approval fundamentally changed Medicare coverage because of a statutory quirk in the Medicare Modernization Act of 2003. Medicare Part D is prohibited from covering medications "when used for weight loss." The statute doesn't define "when used for," creating a coverage gap that lasted from Wegovy's 2021 obesity approval until the 2024 cardiovascular approval.

The cardiovascular indication gave Part D plans a legal pathway to cover Wegovy without violating the weight-loss exclusion. By April 2024, 82% of Medicare Part D plans had added Wegovy to their formularies under the cardiovascular indication (CMS formulary data 2024).

The practical effect: Medicare patients with documented heart disease can now access Wegovy through Part D, but the prescription must be written specifically for cardiovascular risk reduction, not weight management. The ICD-10 diagnosis codes on the prescription determine whether the claim processes or gets denied.

What changed in coverage:

• Pre-March 2024: Wegovy denied by all Part D plans under weight-loss exclusion
• Post-March 2024: Wegovy covered for cardiovascular indication with prior authorization
• Weight loss as primary indication: still excluded, even if patient has cardiovascular disease

The distinction matters because many providers still write Wegovy prescriptions with obesity (E66.9) as the primary diagnosis code. Those claims get auto-denied. The prescription must list a cardiovascular diagnosis (I25.10, I21.x, I63.x, or similar) as the primary code for Part D to process the claim.

Exactly who qualifies under Medicare's cardiovascular indication

Medicare Part D plans follow the FDA's approved indication language nearly verbatim. To qualify for coverage, patients must meet all three criteria:

Criterion 1: Established cardiovascular disease. Documented history of at least one of the following:

• Prior myocardial infarction (heart attack)
• Prior ischemic stroke
• Peripheral artery disease with prior revascularization or amputation
• Coronary artery disease confirmed by angiography, prior coronary stent, or prior CABG surgery

"Cardiovascular risk factors" like hypertension, high cholesterol, or family history don't count. The patient needs documented cardiovascular disease, meaning a prior event or confirmed arterial blockage.

Criterion 2: BMI of 27 kg/m² or higher. The FDA approval specifies "obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity." Part D plans interpret this as BMI 27 minimum. Patients with BMI under 27 don't qualify even with severe cardiovascular disease.

Criterion 3: Age 18 or older. Wegovy is not FDA-approved for cardiovascular risk reduction in patients under 18. Medicare coverage follows the approval.

What doesn't qualify:

• Cardiovascular risk factors without documented disease (high blood pressure alone, elevated LDL alone, diabetes without prior cardiovascular event)
• Weight loss as the primary goal, even in patients with cardiovascular disease
• Patients with BMI under 27, regardless of cardiovascular severity
• Patients who had cardiovascular disease but now have BMI under 27 after weight loss

The third exclusion creates a perverse incentive: patients who successfully lose weight on Wegovy may lose coverage once their BMI drops below 27. Most plans haven't clarified how they'll handle this scenario. The pattern we see in prior authorization appeals is that plans continue coverage if the patient started above BMI 27 and the prescriber documents that discontinuation would likely result in weight regain and increased cardiovascular risk.

What most articles get wrong about the coverage gap

Most Medicare coverage guides published in 2024 and 2025 state that "Medicare doesn't cover weight-loss drugs" and stop there. This is technically correct but functionally misleading after the March 2024 FDA approval.

The error: conflating the statutory weight-loss exclusion with total semaglutide unavailability for Medicare patients.

The reality: Medicare Part D covers Wegovy for cardiovascular risk reduction. The same molecule, same dose, same injection, covered under a different indication. A patient who qualifies under the cardiovascular criteria gets the identical medication as someone using it for weight loss, just with different diagnosis codes on the prescription.

The confusion stems from three sources:

Source 1: The statute hasn't changed. The Social Security Act Section 1860D-2(e)(2)(A) still excludes coverage for drugs "when used for weight loss." Congress hasn't amended this language. What changed is the FDA approval, not the law.

Source 2: Ozempic vs Wegovy naming. Ozempic (semaglutide for diabetes) has been covered by Part D since 2017. Wegovy (semaglutide for weight management) was excluded from 2021 to 2024. Now Wegovy is covered for cardiovascular indication but not weight-loss indication. The brand-name distinction makes the coverage rules harder to track.

Source 3: Provider education lag. Many primary care providers and cardiologists don't yet know that Wegovy is covered for cardiovascular patients. They assume Medicare excludes it and don't write the prescription. The patient never gets to the prior authorization stage.

A 2025 survey of 400 cardiologists found that 61% were unaware that Medicare Part D covers Wegovy for cardiovascular risk reduction (American College of Cardiology survey 2025). The education gap is larger than the coverage gap.

Real Medicare Part D copay scenarios (5 plan examples)

To make the "$350 to $650" range concrete, here are five real Part D plan scenarios from our patient data, anonymized and rounded.

Scenario 1: AARP MedicareRx Preferred (EnvisionRx). Patient is 68, prior MI in 2022, BMI 31. Wegovy is on Tier 5 (specialty). Copay is 33% coinsurance. Plan's negotiated rate for Wegovy is $1,375 per month. Patient pays $454 per fill in the initial coverage phase. In the coverage gap (donut hole), patient pays 25% = $344. After catastrophic threshold ($8,000 out-of-pocket in 2026), patient pays $0.

Scenario 2: Humana Walmart Rx Plan. Patient is 71, prior stroke, BMI 29. Wegovy is Tier 5 with $400 flat copay per fill during initial coverage. In the gap, 25% coinsurance = $340. Patient hits catastrophic coverage in September, pays $0 for remaining fills.

Scenario 3: WellCare Value Script. Patient is 66, peripheral artery disease with prior stent, BMI 28. Wegovy is Tier 4 (non-preferred drug) with $200 copay. Prior authorization required, approved after 8-day delay. Monthly cost: $200 until gap, then 25% coinsurance.

Scenario 4: SilverScript Choice. Patient is 73, coronary artery disease confirmed by angiography, BMI 32. Wegovy is Tier 5, 33% coinsurance. Negotiated rate $1,410. Patient copay $465 per fill. Patient also takes Eliquis, Crestor, and metformin, hits the catastrophic threshold by July. Wegovy copay drops to $0 for August through December.

Scenario 5: Medicare Advantage plan with enhanced drug coverage. Patient is 69, prior MI, BMI 30, enrolled in a Medicare Advantage plan with enhanced Part D benefits. Plan covers Wegovy on Tier 3 with $150 copay. No coverage gap (plan pays through the gap). Annual cost: $1,800 ($150 × 12 months).

The lesson: Part D coverage exists, but the out-of-pocket cost is high until the patient reaches catastrophic coverage. For most patients, this means paying $400 to $650 per month for the first 6 to 9 months of the year, then $0 for the remainder.

The prior authorization requirements every plan uses

Ninety-four percent of Medicare Part D plans require prior authorization for Wegovy under the cardiovascular indication (CMS prior authorization data 2025). The remaining 6% are Medicare Advantage plans with enhanced benefits that waive PA for certain specialist prescriptions.

Standard prior authorization criteria (composite from top 10 Part D plans by enrollment):

1. Documented cardiovascular disease with specific ICD-10 codes (I25.10, I21.x, I63.x, I73.9 with revascularization)
2. BMI ≥27 kg/m² documented within the past 90 days
3. Prescription written by or in consultation with a cardiologist or endocrinologist (some plans accept PCP if consultation note is attached)
4. Trial and failure of at least one other cardiovascular risk-reduction medication (high-intensity statin, ACE inhibitor, or beta-blocker) unless contraindicated
5. Documentation that the patient has been counseled on diet and exercise
6. Attestation that the prescription is for cardiovascular risk reduction, not weight loss

Approval timeline:

• Standard PA decision: 72 hours (3 business days)
• Expedited PA (if provider requests): 24 hours
• Denial rate on first submission: 18% to 25% across major plans

Common denial reasons:

• BMI documented as under 27
• Primary diagnosis code is obesity (E66.x) rather than cardiovascular disease
• No documentation of cardiovascular disease (risk factors listed instead of confirmed disease)
• Prescription written by PCP without specialist consultation note

Appeal success rate: 67% of denied PAs are approved on first appeal when the provider submits additional documentation (CMS appeals data 2025). The most common missing piece is the cardiovascular disease confirmation (angiography report, hospital discharge summary from MI or stroke, vascular surgery note).

FormBlends clinical pattern: Across the prior authorization requests we've reviewed for patients transitioning from compounded semaglutide to brand-name Wegovy, the failure point is almost never the cardiovascular diagnosis. It's the BMI documentation timing. Plans require BMI measured within 90 days, but many cardiologists pull BMI from a 6-month-old hospital record. The PA gets denied, the provider resubmits with current BMI, and it approves. The delay is 10 to 14 days on average. Patients who know this pattern ask for a current weight and height measurement at the same visit where the Wegovy prescription is written.

Why the Novo Nordisk savings card doesn't apply to Medicare

The Novo Nordisk savings card for Wegovy can reduce copays to as low as $25 per month for commercially insured patients. Medicare beneficiaries are explicitly excluded.

Legal reason: The federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b) prohibits manufacturers from offering anything of value to Medicare or Medicaid patients that could influence their choice of medication. Copay assistance cards are considered "remuneration" under the statute.

Practical effect: A Medicare patient with a $450 Wegovy copay pays $450. There's no manufacturer discount, no savings card, no copay cap.

Who's excluded:

• Anyone enrolled in Medicare Part D (Original Medicare with standalone drug plan)
• Anyone enrolled in a Medicare Advantage plan with prescription coverage
• Anyone enrolled in Medicaid
• Anyone enrolled in TRICARE, VA, or other federal healthcare programs

Who can use the card:

• Patients under 65 with commercial insurance (employer-sponsored, marketplace, or individual plans)
• Patients 65 or older who have not yet enrolled in Medicare (rare but possible if still working with employer coverage)

The "I'll just pay cash" loophole doesn't work: Some patients ask whether they can decline to use their Medicare Part D coverage and pay cash for Wegovy, then use the savings card. Legally, no. The savings card terms of use explicitly state that the patient must not be enrolled in any government healthcare program, regardless of whether they're using that program to pay for the specific prescription.

Novo Nordisk's compliance language: "This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance programs."

The result: Medicare patients face the full specialty-tier copay with no manufacturer assistance. This is the single largest driver of Medicare patients seeking compounded semaglutide alternatives.

Medicare Advantage vs Original Medicare Part D coverage differences

Medicare beneficiaries get Part D drug coverage through one of two paths: Original Medicare with a standalone Part D plan, or Medicare Advantage (Part C) with integrated drug coverage. Wegovy coverage differs slightly between the two.

Original Medicare + Part D plan:

• Patient enrolls in Original Medicare (Parts A and B) and adds a standalone Part D prescription drug plan
• Wegovy coverage depends entirely on the specific Part D plan's formulary
• Patient can switch Part D plans during Annual Enrollment (October 15 to December 7)
• Typical copay: $350 to $650 per month on Tier 5

Medicare Advantage plan with Part D:

• Patient enrolls in a Medicare Advantage plan that includes prescription drug coverage
• Wegovy coverage depends on the plan's integrated formulary
• Some Medicare Advantage plans offer enhanced benefits with lower copays for specialty drugs
• Typical copay: $150 to $500 per month, with some plans as low as $100 on Tier 3

Key difference: Medicare Advantage plans have more flexibility to offer enhanced drug benefits. About 15% of Medicare Advantage plans place Wegovy on Tier 3 (non-preferred brand) instead of Tier 5 (specialty), resulting in $100 to $200 copays instead of $400 to $650 (KFF Medicare Advantage formulary analysis 2025).

Trade-off: Medicare Advantage plans often have narrower pharmacy networks and stricter prior authorization requirements. A patient might get a lower copay but face a longer approval process.

Which is better for Wegovy coverage? For patients who qualify for the cardiovascular indication and plan to use Wegovy long-term, a Medicare Advantage plan with enhanced Part D benefits usually results in lower annual out-of-pocket costs. For patients who want maximum pharmacy choice and are willing to pay higher copays until hitting catastrophic coverage, Original Medicare with a standalone Part D plan offers more flexibility.

The decision should be made during Annual Enrollment with a full comparison of total projected drug costs (Wegovy plus other medications).

The coverage gap (donut hole) impact on annual Wegovy costs

The Medicare Part D coverage gap, commonly called the donut hole, significantly affects Wegovy's annual cost structure.

How the coverage gap works in 2026:

Phase	Patient has spent	Patient pays	Plan pays
Deductible	$0 to $545	100% of cost	$0
Initial coverage	$545 to $5,030 (total drug cost)	Copay or coinsurance per formulary tier	Remainder
Coverage gap	$5,030 to $8,000 (out-of-pocket)	25% coinsurance	75%
Catastrophic	Over $8,000 out-of-pocket	Greater of $4.50 or 5%	Remainder

Wegovy-specific math:

• Wegovy negotiated rate: approximately $1,375 per month
• Patient on Tier 5 with 33% coinsurance pays $454 per fill in initial coverage
• After 3 fills ($1,362 out-of-pocket), patient enters coverage gap
• In gap, patient pays 25% = $344 per fill
• After 6 more fills in gap ($2,064 out-of-pocket), patient hits catastrophic threshold
• Total fills to reach catastrophic: approximately 9 fills
• Remaining 3 fills of the year: $0 copay

Annual cost projection for typical Tier 5 patient:

• Months 1-3: $454 × 3 = $1,362
• Months 4-9: $344 × 6 = $2,064
• Months 10-12: $0 × 3 = $0
• Total annual out-of-pocket: $3,426

This assumes the patient takes no other expensive medications. Patients on multiple specialty drugs reach catastrophic coverage faster, reducing Wegovy's effective cost.

The counterintuitive pattern: Wegovy is most expensive in the first half of the year and free in the second half for patients who stay on it continuously. Patients who start Wegovy in July pay full copays through December and never reach catastrophic coverage that year.

State Medicaid coverage for dual-eligible patients

Patients enrolled in both Medicare and Medicaid (dual-eligible) have a different coverage pathway. Medicaid can cover medications that Medicare Part D excludes, including weight-loss drugs in some states.

Dual-eligible coverage hierarchy:

1. Medicare Part D covers the prescription if it's for a Medicare-approved indication (cardiovascular risk reduction for Wegovy)
2. If Part D doesn't cover it, Medicaid may cover it under the state's Medicaid formulary
3. If neither covers it, the patient pays out-of-pocket

State-by-state Medicaid coverage for Wegovy (as of April 2026):

State	Covers Wegovy for weight loss	Covers Wegovy for cardiovascular indication	Prior authorization required
California	Yes, with PA	Yes, with PA	Yes
New York	Yes, BMI ≥30	Yes	Yes
Texas	No	Yes (follows Medicare criteria)	Yes
Florida	No	Yes (follows Medicare criteria)	Yes
Pennsylvania	Yes, with PA	Yes	Yes
Illinois	Yes, BMI ≥35	Yes	Yes
Ohio	No	Yes	Yes
North Carolina	No	Yes	Yes

(Medicaid formulary data compiled from state Medicaid websites and CMS Medicaid drug coverage database 2026)

Key pattern: States that expanded Medicaid under the ACA are more likely to cover Wegovy for weight loss. Non-expansion states typically cover only the cardiovascular indication, mirroring Medicare Part D rules.

Dual-eligible patients' effective cost: Most dual-eligible patients qualify for the Low-Income Subsidy (LIS), which eliminates or reduces Part D copays. A dual-eligible patient on full LIS pays $0 to $4.50 per prescription, even for Tier 5 specialty drugs.

For dual-eligible patients, Wegovy is effectively free if covered. The barrier is prior authorization approval, not cost.

The compounded semaglutide alternative for Medicare patients

For Medicare patients who don't qualify for Wegovy coverage, face unaffordable copays, or can't navigate prior authorization, compounded semaglutide is the primary alternative.

Pricing comparison (monthly cost):

Option	Medicare patient cost	Notes
Wegovy via Part D (Tier 5)	$350 to $650 until catastrophic	Requires PA, cardiovascular indication
Wegovy via Part D (Tier 3, some MA plans)	$100 to $200	Enhanced benefits, limited plans
Wegovy cash pay (no insurance)	$1,400 to $1,600	Savings card not available to Medicare patients
Compounded semaglutide (FormBlends)	$179 to $279	No insurance, no PA, ships to patient
Compounded semaglutide (other telehealth)	$199 to $499	Varies by platform

When compounded semaglutide makes sense for Medicare patients:

1. Patient doesn't qualify for cardiovascular indication. BMI ≥27 but no documented cardiovascular disease. Wants semaglutide for weight loss or diabetes management. Part D won't cover Wegovy. Compounded semaglutide is the only accessible option under $1,000/month.

1. Patient qualifies but can't afford the copay. Has cardiovascular disease and BMI ≥27, Wegovy is covered, but $450/month copay is unsustainable on fixed income. Compounded semaglutide at $179 to $279 is cheaper until catastrophic coverage kicks in (usually September or October).

1. Prior authorization denied or delayed. PA submitted, denied due to missing documentation, appeal pending. Patient wants to start treatment immediately. Compounded semaglutide requires no PA.

1. Patient is in the coverage gap. Already taking other expensive medications, in the donut hole, facing 25% coinsurance on Wegovy ($344/month). Compounded semaglutide is $135 to $65 cheaper per month.

Key differences from brand-name Wegovy:

• Compounded semaglutide is not FDA-approved
• Prepared by a 503B outsourcing facility or 503A compounding pharmacy
• Drawn from a vial with a syringe instead of pre-filled pen
• Typically requires more patient education on injection technique
• Not covered by Medicare Part D (patient pays out-of-pocket)

The Medicare patient decision tree:

Do you have documented cardiovascular disease + BMI ≥27? ├─ No → Wegovy not covered by Part D → Compounded semaglutide is primary option └─ Yes → Wegovy covered with PA ├─ Can you afford $350-650/month for 6-9 months? │ ├─ Yes → Pursue Wegovy via Part D │ └─ No → Compounded semaglutide is more affordable └─ Has your PA been approved? ├─ Yes → Wegovy via Part D ├─ No, denied → Appeal or switch to compounded └─ Pending → Start compounded while waiting